文献速递心律失常

房颤抗凝禁忌患者左心耳封堵的成本效果分析

Cost-effectiveness analysis of left atrial appendage occlusion in patients with atrial fibrillation and contraindication to oral anticoagulation.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究从瑞典医疗与公共部门视角,用决策树联合队列马尔可夫模型评估房颤合并口服抗凝禁忌患者接受经皮左心耳封堵(LAAO)相较标准卒中预防的终生成本与质量调整生命年(QALY)。结果LAAO获得更多QALY(7.11 vs 6.12),医疗视角增量成本约4010欧元、增量成本效果比4047欧元/QALY,公共部门视角LAAO成本更低且健康产出更优。

要点

  • 房颤合并口服抗凝禁忌者,LAAO较标准治疗获得更多QALY(7.11 vs 6.12)。
  • 医疗视角LAAO终生平均成本高约4010欧元,ICER为4047欧元/QALY。
  • 公共部门视角LAAO成本更低且健康产出更优,具成本效果优势。

核心结论

  • 从瑞典医疗与公共部门视角,房颤合并口服抗凝禁忌患者行LAAO相较标准治疗可认为具成本效果。
  • 公共部门视角下LAAO因长期照护支出大幅减少而成本更低且健康产出更优,呈优势策略。
  • 上述结果需在正在进行的随机临床试验同步开展的健康经济学评价中验证。

研究设计与样本

  • 采用决策树联合队列马尔可夫模型,评估终生时限内LAAO与标准治疗的成本与QALY。
  • 研究视角为瑞典医疗体系与公共部门,LAAO治疗效应基于近期一项荟萃分析。
  • 目标人群为房颤且存在口服抗凝禁忌的患者。

主要发现

  • LAAO组QALY为7.11,标准治疗组为6.12。
  • LAAO终生平均医疗成本较标准治疗高约4010欧元。
  • LAAO相较标准治疗的增量成本效果比为4047欧元/QALY。
  • 公共部门视角下LAAO降低平均成本并改善健康产出,呈优势。

临床怎么用

  • 对房颤合并口服抗凝禁忌患者,可将LAAO作为兼顾健康产出与成本的卒中预防选择。
  • 医疗视角下需接受LAAO终生平均医疗成本增加约4010欧元及ICER为4047欧元/QALY。
  • 公共部门决策时可考虑LAAO因长期照护支出减少带来的成本节约。

局限性

  • LAAO治疗效应来自荟萃分析而非同期随机对照试验,需随机试验同步健康经济学评价验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aims to estimate the cost-effectiveness of percutaneous left atrial appendage occlusion (LAAO) compared to standard stroke prevention care for patients with atrial fibrillation (AF) and contraindication to oral anticoagulation (OAC) in a Swedish healthcare and public sector perspective. METHODS AND RESULTS: We used a combined decision tree and cohort Markov model to estimate costs and quality-adjusted life-years (QALYs) over a lifetime horizon with LAAO compared to standard of care where the treatment effect is based on a recent meta-analysis. According to our analysis, LAAO gives more QALYs than standard of care (7.11 vs. 6.12). Furthermore, LAAO treatment is related to the first-year cost of 14 984 Euro (EUR) and higher average healthcare costs over the lifetime by about 4010 EUR, which gives an incremental cost-effectiveness ratio of LAAO vs. standard of care at 4047 EUR per gained QALY. From a public sector perspective, LAAO reduces average costs due to substantial reductions in long-term care and, thus, implies that LAAO is dominant from a public sector perspective (lower average costs and better health outcomes). CONCLUSION: From both Swedish healthcare and public sector perspectives, LAAO can be considered cost-effective compared to standard of care for individuals with AF and contraindication to OAC. However, these results must be confirmed in health economic evaluations alongside the ongoing randomized clinical trials. KEY QUESTION: Is left atrial appendage occlusion (LAAO) cost-effective for patients with atrial fibrillation (AF) and contraindication to oral anticoagulation (OAC) compared to the standard of care from a Swedish healthcare and public sector perspective? KEY FINDING: LAAO is associated with lower cost than the standard of care from a public sector perspective and an incremental cost of 4010 Euro from a healthcare perspective. Furthermore, LAAO is related to better health outcomes than the standard of care. TAKE HOME MESSAGE: Treatment with LAAO among individuals with AF and contraindication to OAC can be considered as cost-effective compared to the standard of care from a Swedish healthcare and public sector perspective.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Labori, Persson, Bonander, et al. Cost-effectiveness analysis of left atrial appendage occlusion in patients with atrial fibrillation and contraindication to oral anticoagulation. Eur Heart J. 2022. PMID: 34919652. doi:10.1093/eurheartj/ehab847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。